Pantoprazol Viatris (Pantoprazole Sodium Sesquihydrate)

Pantoprazole, the active ingredient in Pantoprazol Viatris, is a proton pump inhibitor presented as an oral dosage form for oral use. It treats acid‑related disorders such as gastroesophageal reflux disease, erosive esophagitis, peptic ulcer disease, and Zollinger‑Ellison syndrome in adult patients.

GNH USA supplies Pantoprazol Viatris as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to global quality standards and provides reliable sourcing for regulated markets. It operates across Europe and other regions to meet local demand.

Pantoprazole, a proton pump inhibitor, reduces gastric acid secretion and is indicated for several acid‑related conditions.

- Gastroesophageal reflux disease (GERD): reduces acid exposure, relieving heartburn and esophageal irritation. - Erosive esophagitis: promotes healing of inflamed esophageal tissue by lowering gastric acidity. - Peptic ulcer disease: facilitates ulcer healing and prevents recurrence through sustained acid suppression. - Zollinger‑Ellison syndrome: controls excessive gastric acid production associated with gastrin‑secreting tumors.

Pantoprazole may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Headache: mild pain often transient. - Diarrhea: loose stools that may resolve with continued therapy. - Nause